Skip to content

US · INDP · BIOTECHNOLOGY

Indaptus Therapeutics, Inc. (INDP) intrinsic value and stock valuation

$2.82as of 2026-11-21 · Mkt cap 150.61M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Indaptus Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values INDP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from INDP’s statements →

Indaptus Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10019 indaptusrx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-20.85M
20112025
Free cash flow
-$-14.82M
20112025
Total equity
$3.15M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-19.83M-$-15.37M-$-16.38M-$-14.91M-$-7.73M
Net income-$-20.85M-$-15.02M-$-15.42M-$-14.32M-$-7.71M
EPSd-$-21.49M-$-1.6M-$-1.84M-$-1.73M-$-1.89M
Operating cash flow-$-14.82M-$-12.32M-$-13.41M-$-13.08M-$-11.29M
Capital expenditure-$0.00$0.00$0.00-$-170K-$0.00
Free cash flow-$-14.82M-$-12.32M-$-13.41M-$-13.25M-$-11.29M
Total assets$9.31M$7.34M$14.9M$28.1M$40.6M
Total debt$0.00$80K$180K$80K$170K
Net debt-$-8.51M-$-5.7M-$-13.19M-$-9.55M-$-38.96M
Total equity$3.15M$3.94M$12.1M$24.6M$35.9M
Cash and short-term investments$8.51M$5.79M$13.4M$26.4M$39.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$9.34M$7.25M$7.62M$6.32M$2.52M
Selling, general and administrative expenses$10.5M$8.11M$8.76M$8.59M$5.21M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$19.8M$15.4M$16.4M$14.9M$7.73M
Cost and expenses$19.8M$15.4M$16.4M$14.9M$7.73M
Interest income$0.00$0.00$0.00$590K$20K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Ebitda-$-20.85M-$-15.02M-$-15.42M-$-14.32M-$-7.71M
Operating income-$-19.83M-$-15.37M-$-16.38M-$-14.91M-$-7.73M
Total other income/expenses, net-$-1.02M$340K$960K$590K$20K
Income before tax-$-20.85M-$-15.02M-$-15.42M-$-14.32M-$-7.71M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-20.85M-$-15.02M-$-15.42M-$-14.32M-$-7.71M
Weighted average shares outstanding$970K$9.36M$8.4M$8.26M$4.09M
Weighted average diluted shares outstanding$970K$9.36M$8.4M$8.26M$4.09M
Balance sheet
20252024202320222021
Cash and short-term investments$8.51M$5.79M$13.4M$26.4M$39.1M
Net receivables$0.00$0.00$0.00$0.00$20K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$9.31M$6.62M$14M$27.2M$40.4M
Property, plant and equipment, net$0.00$80K$170K$80K$170K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$720K$930K$820K$190K
Total assets$9.31M$7.34M$14.9M$28.1M$40.6M
Accounts payable$540K$870K$810K$1.38M$2.64M
Short-term debt$0.00$80K$100K$80K$100K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$6.16M$3.39M$2.77M$3.43M$4.6M
Long-term debt$0.00$0.00$70K$0.00$70K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$70K$0.00$70K
Capital lease obligations$0.00$80K$180K$80K$170K
Total liabilities$6.16M$3.39M$2.85M$3.43M$4.68M
Common stock$20K$120K$80K$80K$80K
Retained earnings-$-81.29M-$-60.44M-$-45.42M-$-29.99M-$-15.67M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$100K$0.00
Total equity$3.15M$3.94M$12.1M$24.6M$35.9M
Total investments$0.00$0.00$0.00$16.8M$0.00
Total debt$0.00$80K$180K$80K$170K
Net debt-$-8.51M-$-5.7M-$-13.19M-$-9.55M-$-38.96M
Cash flow statement
20252024202320222021
Net income-$-20.85M-$-15.02M-$-15.42M-$-14.32M-$-7.71M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$1.36M$2.31M$2.97M$2.96M$1.51M
Change in working capital$3.51M$390K-$-520K-$-1.58M-$-5.09M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.85M$470K-$-680K-$-1.15M-$-4.24M
Net cash provided by operating activities-$-14.82M-$-12.32M-$-13.41M-$-13.08M-$-11.29M
Investments in property, plant and equipment$0.00$0.00$0.00-$-170K-$0.00
Acquisitions, net$0.00$0.00$0.00$170K$450K
Net cash used for investing activities$0.00$0.00$17.1M-$-16.43M$450K
Common stock issued$11.8M$5.51M$0.00$0.00$5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$17.5M$4.75M$0.00$0.00$48.3M
Net change in cash$2.72M-$-7.58M$3.74M-$-29.51M$37.5M
Cash at end of period$8.51M$5.79M$13.4M$9.63M$39.1M
Operating cash flow-$-14.82M-$-12.32M-$-13.41M-$-13.08M-$-11.29M
Capital expenditure-$0.00$0.00$0.00-$-170K-$0.00
Free cash flow-$-14.82M-$-12.32M-$-13.41M-$-13.25M-$-11.29M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Indaptus Therapeutics, Inc.

        Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.

        CEO
        Junyi Dai
        Employees
        5
        Beta
        1.14

        Explore

        Frequently asked questions

        What is the intrinsic value of Indaptus Therapeutics, Inc. (INDP)?

        InvestorsCraft does not currently publish an intrinsic value for INDP. How the IC value is calculated.

        Is INDP undervalued?

        InvestorsCraft does not publish an undervaluation signal for INDP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.